Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levoketoconazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 known ✓ | P05093 | 15/20 | 1.00 |
| ▸ | CYP11B1 known ✓ | P15538 | 14/20 | 1.00 |
| ▸ | CYP11B2 known ✓ | P19099 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 19/20 | 1.00 |
| ▸ | CYP21A2 | P08686 | 16/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 16/20 | 1.00 |
| ▸ | USP2 | O75604 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | CYP27B1 | O15528 | 1/20 | 1.00 |
| ▸ | CYP26A1 | O43174 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levoketoconazole SCHEMBL29384825 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 | |
| Levoketoconazole SCHEMBL13606596 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 | |
| Levoketoconazole SCHEMBL13575830 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 | |
| Levoketoconazole SCHEMBL29588034 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 | |
| Ketoconazole SCHEMBL18258319 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 | |
| Ketoconazole SCHEMBL8408 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 | |
| Levoketoconazole SCHEMBL24312989 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 | |
| Levoketoconazole SCHEMBL8407 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 | |
| Levoketoconazole SCHEMBL1517472 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 | |
| Levoketoconazole SCHEMBL11213392 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP21A2CYP19A1CYP17A1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6954 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4149415-B1 | SHAMPOO COMPOSITION COMPRISING ALKYL GLUCOSIDE | PROCTER & GAMBLE (US) | 2026-05-20 | — | — | EP | claimed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-3175865-B1 | FUNCTIONAL PARTICLES, PROCESS TO OBTAIN THEM, AND THEIR APPLICATIONS | SMART INOVATION LDA (PT) | 2026-04-15 | — | — | EP | claimed |
| EP-4337333-B1 | SHAMPOO COMPOSITION | PROCTER & GAMBLE (US) | 2026-04-15 | — | — | EP | claimed |
| EP-3863634-B1 | LEVOKETOCONAZOLE FOR TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA | STRONGBRIDGE DUBLIN LTD (IE) | 2026-04-08 | — | — | EP | claimed |
| EP-4525938-B1 | RADIOPHARMACEUTICAL COMPLEXES TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND ITS COMBINATIONS | BAYER AG (DE) | 2026-03-11 | — | — | EP | claimed |
| EP-4691556-A2 | HUMANIZED ANTI-ACTH ANTIBODIES AND USE THEREOF | H. Lundbeck A/S (DK) | 2026-02-11 | — | — | EP | claimed |
| EP-3634361-B1 | HAIR CARE COMPOSITIONS CONTAINING EXTRACELLULAR METABOLITE PREPARATION FROM BACILLUS COAGULANS | SAMI SABINSA GROUP LTD (IN) | 2026-01-28 | — | — | EP | claimed |
| EP-4149416-B1 | SHAMPOO COMPOSITION COMPRISING DECYL GLUCOSIDE AND A CATIONIC GUAR | PROCTER & GAMBLE (US) | 2026-01-21 | — | — | EP | claimed |
| US-4988697-A | Alpha-demethylase inhibiting azole compound and a beta-lactone | MERCK & CO., INC. (US) | 1991-01-29 | — | — | US | claimed |
| EP-0396184-A2 | Use of ketoconazole and a retinoid for the treatment of acne vulgaris | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-11-07 | — | — | EP | claimed |
| EP-0396251-A2 | Use of fatty acids for the treatment of diseases associated with cytokines | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 1990-11-07 | — | — | EP | claimed |
| EP-0149197-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING DRUGS WHICH ARE SPARINGLY SOLUBLE IN WATER OR INSTABLE AND METHODS FOR THEIR PREPARATION | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-03-21 | — | — | EP | claimed |
| US-4894375-A | FUNGISTATS, KETOCONAZOLE | MERCK & CO., INC. (US) | 1990-01-16 | — | — | US | claimed |
| US-4871741-A | FUNGICIDES; KETOCONAZOLE AND MEVINOLINIC ACID | MERCK & CO., INC. (US) | 1989-10-03 | — | — | US | claimed |
| EP-0315861-A1 | Antimycotic compositions of a nikkomycin compound and an antimycotic azole | BAYER AG (DE) | 1989-05-17 | — | — | EP | claimed |
| US-4782059-A | Method of controlling mycotic infections and compositions therefor | MERCK & CO., INC. (US) | 1988-11-01 | — | — | US | claimed |
| EP-0149197-A2 | Pharmaceutical compositions containing drugs which are sparingly soluble in water or instable and methods for their preparation | JANSSEN PHARMACEUTICA N.V. (BE) | 1985-07-24 | — | — | EP | claimed |
| US-4335125-A | FUNGICIDES, BACTERICIDES | JANSSEN PHARMACEUTICA, N.V. (BE) | 1982-06-15 | — | — | US | claimed |